Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Kaposi's Sarcoma
Conditions
Kaposi's Sarcoma, HIV Infections
Trial Timeline
Apr 1, 2007 → Jul 1, 2012
NCT ID
NCT00444379About Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir is a approved stage product being developed by Merck for Kaposi's Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00444379. Target conditions include Kaposi's Sarcoma, HIV Infections.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00444379 | Approved | Completed |
Competing Products
5 competing products in Kaposi's Sarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Selumetinib | AstraZeneca | Phase 1/2 | 41 |
| Maraviroc | Pfizer | Phase 2 | 51 |
| 50 mg/m2 aldoxorubicin + 100 mg/m2 aldoxorubicin + 150 mg/m2 aldoxorubicin | ImmunityBio | Phase 2 | 49 |
| VEGF inhibitor PTC299 | PTC Therapeutics | Phase 1/2 | 38 |
| Tc 99m tilmanocept | Navidea Biopharmaceuticals | Phase 2 | 44 |